238120 — Aligned Genetics Share Price
- KR₩43bn
- KR₩31bn
- KR₩15bn
- 45
- 52
- 30
- 34
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.31 | ||
Price to Tang. Book | 1.31 | ||
Price to Free Cashflow | 20.98 | ||
Price to Sales | 2.87 | ||
EV to EBITDA | 9.05 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 7.66% | ||
Return on Equity | 10.58% | ||
Operating Margin | 19.15% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | KR₩m | 7,793.68 | 7,957.13 | 11,761.98 | 13,752.58 | 15,214.7 | n/a | n/a | 21.8% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | +578.84 | +1081.59 | -57.84 | +39.61 | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Aligned Genetics Inc, formerly Logos Biosystems Inc, is a Korea-based company engaged in the manufacture and sale of medical equipment. The Company's products mainly consist of automated cell counters, such as LUNA, LUNA-FL, LUNA-STEM, LUNA-II, LUNA- YF, QUANTOM, tissue clearing systems, such as X-CLARITY, and digital cell imaging systems, such as iRiS.
Directors
- Yeon Cheol Jung CEO (46)
- Gyeong Taek Kim OTH (42)
- Byeong Seong Cho DRC (44)
- Geun Chang Cho DRC (48)
- Yeon Seok Jung DRC (43)
- Seong Cheol Park DRC (52)
- Nu Ri Jeon NID (47)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- October 2nd, 2008
- Public Since
- November 3rd, 2016
- No. of Shareholders
- 4,471
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 14,378,896
- Address
- 2/3F, ANYANG, 14055
- Web
- https://alignedgenetics.com/
- Phone
- +82 314784185
- Auditors
- Sahmduk Accounting Corp.
Upcoming Events for 238120
Similar to 238120
Access Bio
Korea Exchange - KOSDAQ
Alphanox Co
Korea Exchange - KOSDAQ
Angel Robotics Co
Korea Exchange - KOSDAQ
Asta Co
Korea Exchange - KOSDAQ
Biodyne Co
Korea Exchange - KOSDAQ
FAQ
As of Today at 18:13 UTC, shares in Aligned Genetics are trading at KR₩2,985. This share price information is delayed by 15 minutes.
Shares in Aligned Genetics last closed at KR₩2,985 and the price had moved by -21.1% over the past 365 days. In terms of relative price strength the Aligned Genetics share price has underperformed the FTSE Developed Asia Pacific Index by -30.39% over the past year.
The overall consensus recommendation for Aligned Genetics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAligned Genetics does not currently pay a dividend.
Aligned Genetics does not currently pay a dividend.
Aligned Genetics does not currently pay a dividend.
To buy shares in Aligned Genetics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩2,985, shares in Aligned Genetics had a market capitalisation of KR₩43bn.
Here are the trading details for Aligned Genetics:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 238120
Based on an overall assessment of its quality, value and momentum Aligned Genetics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aligned Genetics. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -33.05%.
As of the last closing price of KR₩2,985, shares in Aligned Genetics were trading -22.38% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Aligned Genetics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩2,985.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Aligned Genetics' management team is headed by:
- Yeon Cheol Jung - CEO
- Gyeong Taek Kim - OTH
- Byeong Seong Cho - DRC
- Geun Chang Cho - DRC
- Yeon Seok Jung - DRC
- Seong Cheol Park - DRC
- Nu Ri Jeon - NID